0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Deferasirox"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
From
EUR$3,545USDGBP
EUR$3,939USDGBP
From
EUR$3,545USDGBP
EUR$3,939USDGBP
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Medical Deferoxamine Mesylate Global Market Report 2025 - Product Thumbnail Image

Medical Deferoxamine Mesylate Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
EUR$4,490USDGBP
Deferiprone - Global Strategic Business Report - Product Thumbnail Image

Deferiprone - Global Strategic Business Report

  • Report
  • July 2025
  • 359 Pages
  • Global
From
EUR$5,850USDGBP
Thalassemia Market Report and Forecast 2025-2034 - Product Thumbnail Image

Thalassemia Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
EUR$4,949USDGBP
From
EUR$6,499USDGBP
From
EUR$4,750USDGBP
  • 12 Results (Page 1 of 1)
Loading Indicator

Deferasirox is a hematological drug used to treat iron overload caused by blood transfusions. It is an oral chelator that binds to iron and helps the body to excrete it. Deferasirox is used to reduce iron levels in patients with thalassemia, sickle cell anemia, and other conditions that require frequent blood transfusions. It is also used to treat iron overload in patients with myelodysplastic syndromes and other conditions. Deferasirox is available in tablet form and is taken once daily. Deferasirox is a relatively new drug and is not yet widely available. It is approved for use in the United States, Europe, and other countries. The drug is generally well tolerated, with the most common side effects being nausea, vomiting, and diarrhea. Some companies in the Deferasirox market include Novartis, Teva Pharmaceuticals, and Mylan. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more